Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · IEX Real-Time Price · USD
2.040
+0.110 (5.70%)
At close: Apr 26, 2024, 4:00 PM
2.012
-0.028 (-1.37%)
After-hours: Apr 26, 2024, 7:09 PM EDT
Coherus BioSciences Revenue
In the year 2023, Coherus BioSciences had annual revenue of $257.24M with 21.89% growth. Revenue in the quarter ending December 31, 2023 was $91.52M with 101.81% year-over-year growth.
Revenue (ttm)
$257.24M
Revenue Growth
+21.89%
P/S Ratio
0.90
Revenue / Employee
$840,667
Employees
306
Market Cap
231.54M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 257.24M | 46.20M | 21.89% |
Dec 31, 2022 | 211.04M | -115.51M | -35.37% |
Dec 31, 2021 | 326.55M | -149.27M | -31.37% |
Dec 31, 2020 | 475.82M | 119.75M | 33.63% |
Dec 31, 2019 | 356.07M | - | - |
Dec 31, 2018 | 0 | - | - |
Dec 31, 2017 | 1.56M | -188.55M | -99.18% |
Dec 31, 2016 | 190.11M | 160.07M | 532.82% |
Dec 31, 2015 | 30.04M | -1.07M | -3.42% |
Dec 31, 2014 | 31.11M | 28.36M | 1,030.72% |
Dec 31, 2013 | 2.75M | 852.00K | 44.87% |
Dec 31, 2012 | 1.90M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Auna S.A. | 1.04B |
Accuray | 447.48M |
23andMe Holding Co. | 247.99M |
2seventy bio | 100.39M |
Foghorn Therapeutics | 34.16M |
Senseonics Holdings | 22.39M |
uniQure | 15.84M |
CHRS News
- 2 days ago - Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 19 days ago - Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting - GlobeNewsWire
- 6 weeks ago - Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update - GlobeNewsWire
- 7 weeks ago - Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024 - GlobeNewsWire
- 7 weeks ago - Coherus Completes Divestiture of Ophthalmology Franchise - GlobeNewsWire
- 2 months ago - Coherus BioSciences Announces New Employment Inducement Grants - GlobeNewsWire
- 2 months ago - Coherus Announces U.S. Launch of UDENYCA ONBODY™ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv - GlobeNewsWire
- 2 months ago - Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP - GlobeNewsWire